NanoViricides, Inc. (NASDAQ:NNVC) | Finanzwire

Basculer en Français

11247	Companies
249737	Keywords
177919	Articles
135560	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 01/29/2024 at 12:30, 2 years 9 months ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV

NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
PRESS RELEASE

published on 01/04/2024 at 12:30, 2 years 9 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco
NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections.

NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE

published on 11/28/2023 at 12:40, 2 years 11 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE

published on 11/15/2023 at 12:45, 2 years 11 months ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE

published on 11/14/2023 at 12:45, 2 years 11 months ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE

published on 10/16/2023 at 12:45, 3 years ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE

published on 10/12/2023 at 12:45, 3 years ago

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE

published on 08/21/2023 at 12:45, 3 years 2 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE

published on 07/11/2023 at 12:45, 3 years 3 months ago

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE

published on 07/06/2023 at 12:45, 3 years 3 months ago

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

Accesswire

Published on 10/29/2026 at 22:01, 4 hours 45 minutes ago

Pinetree Capital Announces Unaudited Financial Results for the Period Ended September 30, 2026
Published on 10/29/2026 at 22:00, 4 hours 46 minutes ago

PPX Mining Announces Debt Settlement
Published on 10/29/2026 at 21:30, 5 hours 16 minutes ago

Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 8 hours 16 minutes ago

Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 10 hours 41 minutes ago

SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date

View all ACCESSWIRE

EQS Group

Published on 10/29/2026 at 22:25, 4 hours 20 minutes ago

SFC Energy continues strong, profitable growth in the first nine months of 2026 – preliminary figures – earnings guidance raised again
Published on 10/29/2026 at 22:21, 4 hours 25 minutes ago

EQS-Adhoc: SFC Energy AG raises full-year 2026 earnings guidance again
Published on 10/29/2026 at 21:29, 5 hours 17 minutes ago

2CRSi SA: Publication of the consolidated annual results and the 2025-2026 Annual Financial Report postponed to 30 October 2026
Published on 10/29/2026 at 21:20, 5 hours 26 minutes ago

2CRSi SA: 2CRSi publishes the conclusions of the independent expert appointed following the Grizzly Research report and provides clarifications on several previous communications
Published on 10/29/2026 at 20:13, 6 hours 33 minutes ago

Interim individual financial statements of Sirma Group JSC for the period ending on September 30, 2026

Les Echos

Published on 10/29/2026 at 18:02, 8 hours 44 minutes ago

TF1 9M 2026 results - Consolidated financial statements and appendix
Published on 10/29/2026 at 18:00, 8 hours 46 minutes ago

GUILLEMOT CORPORATION: THIRD-QUARTER 2026 TURNOVER / Successful new product launches and acceleration of international commercial partnerships
Published on 10/29/2026 at 17:45, 9 hours ago

AXA - 9M26 Activity Indicators
Published on 10/29/2026 at 17:45, 9 hours 1 minute ago

ENGIE commissions 450 MW of solar capacity in India
Published on 10/29/2026 at 17:45, 9 hours 1 minute ago

3rd quarter 2026 revenue

View all LES ECHOS COMFI WIRE